Journal Watch · Nature Communications · 2026

ProFormer: generalizable classification of single-cell and plasma proteomes using deep learning.

Thereby, the ProFormer provides a versatile and rapid framework for the classification of proteomic data, with important implications for patient stratification, early detection and single-cell analysis.

Krull KK, Kühn A, Höhn J et al.Nature Communications3 min readPharma relevance 50/100

DOI: 10.1038/s41467-026-78143-2PMID: 42834055Study type: cohort / observational clinical study

TL;DR

Thereby, the ProFormer provides a versatile and rapid framework for the classification of proteomic data, with important implications for patient stratification, early detection and single-cell analysis.

Key findings

  • Applied to diverse LC-MS data sets, the ProFormer accurately classified single-cell proteomes by cell type, cycle stage or differentiation trajectory, as well as patient disease status from plasma proteomes.
  • Thereby, the ProFormer provides a versatile and rapid framework for the classification of proteomic data, with important implications for patient stratification, early detection and single-cell analysis.

What they did

Specifically, we introduce the ProFormer, a transformer pipeline that classifies samples by tabular MS1-level features derived from peptide ions, eliminating the need for time-consuming data interpretation. The ProFormer outperforms traditional machine-learning and image-based convolutional neural networks (CNNs), demonstrating enhanced classification and generalization over 14 evaluated architectures. We further provide detailed insights into how the ProFormer dynamically aggregates MS1 data, while preserving signal contribution and enabling explainable AI at single-peptide resolution.

Full abstract (original)

Background: Proteins are the main drivers of cell function and disease, making proteomics a powerful technique for biomarker discovery and defining cell identity. While current technologies can profile thousands of proteins and reach single-cell sensitivity, limited throughput restricts applications such as robust classification of large biological or clinical cohorts. To close this gap, we present a deep-learning (DL) approach for the direct analysis of mass spectrometric (MS) data, assigning proteomic profiles to sample identity.

What they did: Specifically, we introduce the ProFormer, a transformer pipeline that classifies samples by tabular MS1-level features derived from peptide ions, eliminating the need for time-consuming data interpretation. The ProFormer outperforms traditional machine-learning and image-based convolutional neural networks (CNNs), demonstrating enhanced classification and generalization over 14 evaluated architectures. We further provide detailed insights into how the ProFormer dynamically aggregates MS1 data, while preserving signal contribution and enabling explainable AI at single-peptide resolution.

Results & conclusions: Applied to diverse LC-MS data sets, the ProFormer accurately classified single-cell proteomes by cell type, cycle stage or differentiation trajectory, as well as patient disease status from plasma proteomes. Thereby, the ProFormer provides a versatile and rapid framework for the classification of proteomic data, with important implications for patient stratification, early detection and single-cell analysis.

Abstract © the authors / Nature Communications (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41467-026-78143-2 · PubMed 42834055.

Why it matters for pharma & biotech

  • Directly relevant to teams in AI in drug discovery / diagnostics — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: AI in drug discovery / diagnostics

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Communications study find?

Thereby, the ProFormer provides a versatile and rapid framework for the classification of proteomic data, with important implications for patient stratification, early detection and single-cell analysis.

What type of study is this?

It is a cohort / observational clinical study, published in Nature Communications in 2026. Specifically, we introduce the ProFormer, a transformer pipeline that classifies samples by tabular MS1-level features derived from peptide ions, eliminating the need for time-consuming data interpretation.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41467-026-78143-2. PubMed ID: 42834055. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Krull KK, Kühn A, Höhn J et al.. ProFormer: generalizable classification of single-cell and plasma proteomes using deep learning.. Nature Communications (2026). DOI: 10.1038/s41467-026-78143-2.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/proformer-generalizable-classification-of-single-cell-and-plasma-proteom-781432/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides